HFOV in premature neonates: effects on pulmonary mechanics and epithelial lining fluid cytokines. A randomized controlled trial

Intensive Care Med. 2005 Mar;31(3):463-70. doi: 10.1007/s00134-005-2556-x. Epub 2005 Feb 17.

Abstract

Objective: Ventilation strategies for preterm neonates may influence the severity of pulmonary dysfunction and later development of chronic lung disease. The objective of this report is to compare the effects of high-frequency oscillatory ventilation (HFOV) versus synchronized intermittent mandatory ventilation (sIMV) from the points of views of biochemical and functional variables.

Design: Randomized controlled trial.

Setting: Third level NICU.

Patients and participants: Forty preterm neonates with a gestational age of 24-29 weeks were randomly assigned to one of the two above-mentioned ventilation strategies within 30 min from birth.

Measurements and results: At 1, 3, 5, and 7 days, the babies were monitored by means of ventilator indices, pulmonary function, and eight pro-inflammatory or anti-inflammatory cytokines measured in bronchoalveolar lavage fluid. The neonates assigned to the HFOV procedure benefited from early and sustained improvement in pulmonary mechanics and gas exchange-significantly higher dynamic respiratory compliance values, significantly lower expiratory airway resistance and oxygenation index values-with earlier extubation as compared to the neonates assigned to sIMV treatment, and showed significantly lower transforming growth factor-beta1 concentrations in bronchoalveolar lavage fluid.

Conclusions: The results of this randomized clinical trial support the hypothesis that early and exclusive use of HFOV, combined with optimum volume strategy, has a beneficial effect during the acute phase of lung injury.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Body Fluids / metabolism
  • Cytokines / metabolism*
  • Female
  • High-Frequency Ventilation*
  • Humans
  • Infant, Newborn
  • Infant, Premature, Diseases / immunology
  • Infant, Premature, Diseases / physiopathology
  • Infant, Premature, Diseases / therapy*
  • Male
  • Respiration, Artificial / methods
  • Respiratory Distress Syndrome, Newborn / immunology
  • Respiratory Distress Syndrome, Newborn / physiopathology
  • Respiratory Distress Syndrome, Newborn / therapy*
  • Respiratory Mechanics
  • Respiratory Mucosa / immunology*
  • Respiratory Mucosa / metabolism*
  • Survival Analysis
  • Transforming Growth Factor beta / metabolism
  • Transforming Growth Factor beta1
  • Treatment Outcome

Substances

  • Cytokines
  • TGFB1 protein, human
  • Transforming Growth Factor beta
  • Transforming Growth Factor beta1